Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer

For patients with EGFR PACC-mutated non-small cell lung cancer (NSCLC), the targeted therapy firmonertinib achieved durable antitumor activity in a Phase Ib trial led by researchers at The University of Texas MD Anderson Cancer…